Top Markets
#1 Nesa Nesa +485.04%
#2 Black Phoenix Black Phoenix +193.70%
#3 MetaDAO MetaDAO +29.96%
#4 Ontology Gas Ontology Gas +20.60%
#5 Bedrock Bedrock +18.87%
#6 Stacks Stacks +16.84%
#7 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +16.07%
#8 Prom Prom +14.68%
#9 Purr Purr +13.08%
#10 Pons Pons +12.79%
Coin of the day
Nesa Nesa
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Abiomed, Inc. Abiomed, Inc.

Abiomed, Inc.

ABMD
Kedudukan dalam Saham #1388
Abiomed, Inc. specializes in the creation and distribution of advanced medical... Abiomed, Inc. specializes in the creation and distribution of advanced medical technology designed to support or substitute the heart's pumping action in patients suffering from heart failure, while also offering ongoing care for these individuals. Its product portfolio includes various devices from the Impella family. The Impella 2.5 is a tiny percutaneous heart pump featuring an integrated motor and sensors, alongside the Impella CP, which is utilized by interventional cardiologists in catheterization labs and by cardiac surgeons during operations. Other Impella models such as the 5.0, LD, and 5.5 are also percutaneous micro heart pumps, primarily employed in surgical settings. The Impella RP is a percutaneous catheter-based axial flow pump. Beyond the pumps, Abiomed offers the Impella SmartAssist platform, which leverages optical sensors for precise pump placement and uses algorithms to enhance native heart function assessment during patient weaning. Its Impella Connect system provides secure, cloud-based remote monitoring of the automated Impella controller for medical staff. The company also markets the OXY-1 System, a portable device for external respiratory support. Furthermore, Abiomed is actively developing several innovations, including the Impella ECP pump for high blood flow rates, the Impella XR Sheath for smaller access during Impella procedures, the Impella BTR percutaneous micro heart pump, and preCARDIA, a catheter-based superior vena cava therapy system aimed at quickly addressing acute decompensated heart failure. Abiomed distributes its products globally through its dedicated direct sales and clinical support teams, reaching regions such as the United States, Japan, Canada, countries across Europe (including Germany and France), Latin America, the Asia-Pacific, and the Middle East. Founded in 1981 and headquartered in Danvers, Massachusetts, Abiomed, Inc. has been operating as a subsidiary of Johnson & Johnson since December 22, 2022.
Harga Saham
$381.02
Disegerakkan terakhir: 2022-12-23
Modal Pasaran
$17.18B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Abiomed, Inc. (ABMD)

Kategori

Healthcare
Nisbah P/E bagi Abiomed, Inc. (ABMD)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Abiomed, Inc., nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi Abiomed, Inc. dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Abbott Laboratories Abbott Laboratories
Abbott Laboratories
ABT.US
 35.77 -
US
Stryker Corporation Stryker Corporation
Stryker Corporation
SYK.US
 34.86 -
US
Medtronic plc Medtronic plc
Medtronic plc
MDT.US
 21.39 -
IE
Boston Scientific Corporation Boston Scientific Corporation
Boston Scientific Corporation
BSX.US
 20.90 -
US
Siemens Healthineers AG Siemens Healthineers AG
Siemens Healthineers AG
SHL.DE
 - -
DE
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.